{"preliminary_commentary":{"by_channel":{"youtube":3,"x_thread":2,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"RADIAN","nct_id":"NCT05784012","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=radian-nct05784012. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"RADIAN","arms":[{"description":"Three stages:\n\nNeoadjuvant: single dose of dostarlimab 500 mg intravenously on day -21 and niraparib 200 or 300 mg orally once daily starting on day -14 until 48 hours prior to the start of definitive radiotherapy (day 0).\n\nConcurrent: definitive radiotherapy (70 Gy in 35 fractions, 1 fraction per day from Monday to Friday) with concurrent Cisplatin at a dose of 100 mg/m2 intravenously on day 1 of week 1, week 4 and week 7.\n\nMaintenance: dostarlimab to be administered as a single infusion dose of 500 mg on day 1 every 21 days from week 11 to week 48. Niraparib will be given once daily at a dose of 200 or 300 mg in cycles of 21 days.","label":"Cohort A","type":"EXPERIMENTAL"},{"description":"Three stages:\n\nNeoadjuvant: single dose of dostarlimab 500 mg intravenously on day -21 and niraparib 200 or 300 mg orally once daily starting on day -14 until the start of definitive radiotherapy (day 0).\n\nConcurrent: definitive radiotherapy (70 Gy in 35 fractions, 1 fraction per day from Monday to Friday). Niraparib is to be given once daily on a continous basis (200 to 300 mg), from w1 d1 until end of w10 in cycles of 21 days.\n\nMaintenance: dostarlimab to be administered as a single infusion dose of 500 mg on day 1 every 21 days from week 11 to week 48. Niraparib will be given once daily on a continous basis at a dose of 200 or 300 mg in cycles of 21 days.","label":"Cohort B","type":"EXPERIMENTAL"}],"collaborators":["GlaxoSmithKline","MFAR"],"completion_date":{"date":"2029-03","type":"ESTIMATED"},"conditions":["Head and Neck Squamous Cell Carcinoma"],"enrollment":{"count":34,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Dostarlimab","otherNames":[],"type":"DRUG"},{"name":"Niraparib","otherNames":[],"type":"DRUG"},{"name":"cisplatin plus radiotherapy","otherNames":[],"type":"DRUG"},{"name":"Niraparib","otherNames":[],"type":"DRUG"}],"last_update":"2026-06-04","lead_sponsor":"Grupo Español de Tratamiento de Tumores de Cabeza y Cuello","official_title":"Phase Ib/II Non-randomized Non-comparative Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2027-03","type":"ESTIMATED"},"primary_outcomes":[{"measure":"1-year disease free survival","timeFrame":"1 year after the start of the study treatment"}],"references":[],"start_date":{"date":"2023-11-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT05784012"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/radian-nct05784012"}